Open AccessResumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
Author(s) -
Maegawa Yoko,
Kato Taigo,
Fukuhara Shinichiro,
Kiuchi Hiroshi,
Imamura Ryoichi,
Uemura Motohide,
omura Norio,
Fujita Kazutoshi
Publication year - 2020
Publication title -
iju case reports
Language(s) - English
Resource type - Journals
ISSN - 2577-171X
DOI - 10.1002/iju5.12173
Subject(s) - medicine , discontinuation , adverse effect , nivolumab , combination therapy , renal cell carcinoma , immune system , cytotoxic t cell , immunology , gastroenterology , oncology , immunotherapy , biology , biochemistry , in vitro
Combined anti‐cytotoxic‐T‐lymphocyte antigen 4 and programmed cell death 1 blockade induced high rates of immune‐related adverse events in patients with renal cell carcinoma. However, the safety of reinitiating anti‐programmed cell death 1 monotherapy for patients who discontinued combination therapy due to immune‐related adverse events is largely unknown. Case presentation We report the case of 74‐year‐old man who received combination therapy with anti‐cytotoxic‐T‐lymphocyte antigen 4 and programmed cell death 1 inhibitors for advanced renal cell carcinoma. After three cycles of combination therapy, he complained severe immune‐related adverse events including grade 3 nausea and anorexia, and grade 3 diarrhea, leading to discontinuation of the therapy. He started readministration of anti‐programmed cell death 1 monotherapy at 41 weeks after discontinuation due to the new lung metastatic lesion. Importantly, he experienced only grade 1 diarrhea, which can be controlled with prednisolone. Conclusion The readministration of anti‐programmed cell death 1 monotherapy with close monitoring can be an acceptable treatment even after discontinuation of combination therapy.